cpix stock: CPIX (Cumberland Pharmaceuticals)

CPIX (Cumberland Pharmaceuticals, Inc.)

cpix stock refers to the NASDAQ-listed common shares trading under the ticker CPIX and represents investors’ exposure to Cumberland Pharmaceuticals, Inc., a U.S.-based specialty pharmaceutical company focused on marketed branded hospital and supportive-care products and clinical-stage rare-disease programs. Readers will learn the company overview, history, principal products, R&D priorities, financial and trading facts, recent developments (with dates), governance notes, and investor considerations. The term cpix stock appears throughout to help locate relevant trading and corporate information.

Company overview

Cumberland Pharmaceuticals is a specialty pharmaceutical company headquartered in Nashville, Tennessee. The firm focuses on hospital acute care, gastroenterology, oncology supportive care, and rare-disease programs. The equity is commonly searched as cpix stock on market-data platforms and investor pages.

History

Founded in the 1990s, Cumberland built a portfolio of branded hospital and supportive-care medicines. The company completed its public listing under the ticker CPIX on the NASDAQ, expanded its marketed portfolio through targeted acquisitions and licensing, and advanced several clinical-stage programs in rare diseases.

Key historical milestones

• IPO/listing as CPIX on NASDAQ (ticker CPIX).
• Regulatory approvals for marketed hospital products and supportive-care medicines.
• Addition of rare-disease development programs (ifetroban and others).
• Presentations of pivotal trial readouts and orphan-drug designations (see timeline in company releases).

Products and marketed portfolio

Cumberland’s marketed products include hospital and supportive-care brands used in acute care and specialty settings. Representative marketed products and typical indications: Acetadote (treatment for acetaminophen toxicity), Caldolor (IV analgesic/antipyretic), Kristalose (constipation/colonic evacuation), Sancuso (chemotherapy-induced nausea prevention), Vaprisol (hyponatremia), Vibativ (antibacterial), and other specialty products. Each product contributes variably to revenue; cpix stock performance often reflects the commercial traction of these products.

Research and development programs

Cumberland’s R&D centers on rare-disease indications and hospital-focused therapeutics. Lead clinical programs include ifetroban development for cardiomyopathy in Duchenne muscular dystrophy and other fibrotic/rare indications; certain programs have received orphan or rare pediatric designations. R&D progress and trial phases are disclosed in company press releases and SEC filings.

Business model and strategy

The company’s revenue model combines commercial sales of branded products, licensing/partnership agreements, and clinical development value creation. Cumberland pursues hospital-channel penetration, label-expansion, and strategic partnerships to grow revenue—factors commonly analyzed by holders of cpix stock.

Financial performance

Financial results vary by reporting date; Cumberland’s SEC filings (10-Q, 10-K) and investor releases provide quarterly and annual figures. As of the most recent filings, the company has reported revenue from its marketed portfolio alongside investment in R&D. Profitability and cash position fluctuate across periods; investors in cpix stock should consult the latest filings for up-to-date figures.

Stock information

• Market listing/ticker: NASDAQ: CPIX (cpix stock).
• 52-week range (approximate): $1.04–$7.25 (as reported by market-data providers; check the reporting date).
• Market capitalization: small-cap range (figures change daily; see market-data pages for current valuation).
• Valuation metrics: trailing P/E and EPS have been negative in recent reported periods for some quarters, reflecting R&D and operating dynamics.

Historical share-price performance

cpix stock has experienced volatility driven by quarterly results, trial readouts, regulatory announcements, and product news; spikes and dips correspond to material company updates and market reactions.

Analyst coverage and price targets

Analyst coverage is limited compared with large-cap peers. Any available one-year price targets or analyst counts should be verified on financial-data platforms and change over time.

Major news and recent developments

• As of 2026-01-29, Cumberland’s investor page and market reports summarized recent quarterly results and program updates (see References). cpix stock movements have tracked trial data releases, orphan-drug designations, and commercial performance updates.

Corporate governance and management

Cumberland’s leadership and board details are published in SEC filings and the company’s investor relations materials. Executive biographies and management changes are reported by the company and in regulatory filings.

Ownership and holders

Institutional and insider holdings for cpix stock are reported on market-data platforms and in proxy/SEC filings; ownership levels are time-sensitive and disclosed periodically.

Trading, liquidity and investor considerations

cpix stock typically exhibits low to moderate average daily volume relative to large-cap equities; liquidity and thin float can amplify price moves. Key investor considerations include clinical/regulatory risk, revenue concentration in a few products, and upcoming trial or regulatory catalysts.

Legal, regulatory and compliance matters

Products and development programs are subject to FDA and international regulatory review. Material regulatory events and compliance disclosures are made in company press releases and SEC filings.

Controversies and litigation

Any material litigation or regulatory actions are disclosed in SEC filings. No additional specific controversies are included here; refer to company disclosures for details.

See also

Related topics: small-cap specialty pharmaceutical companies, orphan-drug designation, Duchenne muscular dystrophy research.

References

• Company investor relations page and press releases (SEC filings, 10-Q/10-K) — primary factual source for corporate, financial, and program information.
• Market-data pages and quotes (Yahoo Finance, Nasdaq, CNBC, Robinhood, Stocktwits) for trading metrics and 52-week range (check reporting date on each platform).
• Analyst and news summaries (StockTitan, Intellectia.ai, Public.com) for coverage notes and recent headlines.

(As of 2026-01-29, readers should consult the listed sources directly for the most current metrics; statements above reference those sources and the company’s filings.)

External links

• Cumberland Pharmaceuticals investor relations (official site)
• Market-data quote pages (Yahoo Finance, Nasdaq, CNBC)
• Recent press releases and earnings call transcripts